Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Clinical trial NCT06074588 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06074588
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-12
- Primary completion
- 2027-05-10
- Enrollment
- 556
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.